Developer docs
API playgroundTry for free, no card

Search company profiles

21st.BIO

Full company profile

uuid00008fm

Namestring
21st.BIO
Legal namestring
21st.BIO
Websiteurl
21st.bio
Company typeenum
Private
Founded yearint
2020
Descriptiontext

21st.BIO is a Danish precision fermentation technology and contract development company founded in 2020 and headquartered in Søborg, Denmark, with a US commercial office in Davis, California. The company operates a B2B platform that helps startups, ingredient suppliers, and large food/agriculture manufacturers bridge the 'valley of death' between lab-scale molecular innovation and industrial-scale protein production. Its stated customers include precision fermentation developers of dairy proteins, biomaterials, agricultural biocontrols, sweeteners, collagen, and biomining reagents.

The technology platform rests on three pillars: (1) microbial production strains licensed from Novozymes (now Novonesis) that have been genome-optimized over more than 40 years and are already used in food-grade products on the market today; (2) optimized fermentation processes; and (3) downstream recovery and purification (DSP) workflows built for scalability. 21st.BIO inherited the team of microbiologists and bioengineers who developed the strains at Novozymes, giving the company unusual institutional process knowledge. In May 2024 it opened a 3,060L pilot plant at its Copenhagen headquarters, designed as a 'mini factory' to de-risk customers' tech transfer to contract manufacturers. Named technical milestones include the world's first extracellular expression of spider silk proteins (with AMSilk) and customer market entry for beta-lactoglobulin in under two years from start of strain engineering.

21st.BIO earns revenue through three channels: (a) shared-cost Development Programs for nature-identical molecules such as BLG Essential+, alpha-lactalbumin, caseins, and protein sweeteners, where multiple participants pay upfront development fees and receive ongoing licensing access to continuously optimized strains and processes; (b) bespoke Custom Development Projects for proprietary customer proteins, priced per project milestones; and (c) quote-based Pilot Plant Services offering fermentation runs up to 1,200L, DSP equipment rental, and CMO tech-transfer support. The business model is explicitly backloaded to follow customers' commercial journey, aligning 21st.BIO's monetization with downstream product success. EUR 86 million in funding from Novo Holdings (December 2021) is allocated to capacity expansion and construction of the company's first manufacturing site.

Short descriptiontext

21st.BIO is a Danish precision fermentation technology company that licenses 40+ year-old microbial strains from Novonesis to deliver industrial-scale bioproduction services for dairy proteins, biomaterials, agricultural biocontrols, sweeteners, and other recombinant proteins.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSøborg, Denmark
HQ citystring
Søborg
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision fermentation services, industrial biotechnology, microbial strain engineering, recombinant protein production, fermentation scale-up
Industry4 codes
PRIMARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYAFAJAHAH
Fermentation-Derived Proteins (Precision Fermentation, Biomass Fermentation)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFAJAHAL
Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Food And Kindred Products2000
Product category
Industrial Biotechnology / Precision Fermentation Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Development Programs (Nature-Identical Molecules)
TypeLicensing Royalties
Description

21st.BIO selects a few natural proteins (e.g., beta-lactoglobulin, caseins) to be offered through development programs. Several companies share development costs, gaining access to continuously optimized technology and a license to use the strains and processes. This shared-cost model significantly de-risks investment into precision fermentation production. Participants pay an upfront development fee and receive ongoing access to technology optimization.

21st.bio
2Custom/Bespoke Development Projects
TypeProfessional Services
Description

Individually designed projects to optimize a customer's proprietary recombinant protein. Dedicated project to a single customer encompassing activities including strain optimization, production process design, DSP development, and technology upscaling. Priced as a custom engagement; revenue recognized upon project milestones.

21st.bio
3Pilot Plant Services
TypeProfessional Services
Description

21st.BIO offers bioproduction upscaling services at its Copenhagen pilot facility, including fermentation runs up to 1,200L and DSP equipment rental. Services are available to customers with their own proprietary strains as well as existing customers in development programs. Pricing is quote-based, tailored to fermenter volumes, process time, material handling, DSP equipment, and special support needs.

21st.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1BLG Essential+™
Description

A high-leucine, animal-free beta-lactoglobulin produced through precision fermentation, designed for food applications including healthy aging and GLP-1 nutrition.

21st.bio
Core offering1 text field

21st.BIO provides industrial-scale precision fermentation technology and services for protein and peptide production, combining 40+ year-old microbial production strains licensed from Novozymes/Novonesis with optimized fermentation processes and downstream recovery/purification workflows. Customers engage through shared-cost Development Programs for nature-identical molecules (BLG, alpha-lactalbumin, caseins, sweeteners, collagen, biomaterials, biomining proteins) or through bespoke Custom Development Projects for proprietary proteins, supported by a 3,060L Copenhagen pilot plant for upscaling and tech transfer to contract manufacturers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Market entry achieved in under two years from start of strain engineering for beta-lactoglobulin customers
+5 more records
Product overview1 text field

21st.BIO operates a precision fermentation technology platform that provides end-to-end solutions for industrial-scale protein and peptide production. The platform consists of proprietary production strains licensed from Novonesis (with 40+ years of optimization), optimized fermentation processes, and downstream processing (DSP) workflows. The company offers two engagement models: shared-cost Development Programs for nature-identical molecules (including BLG Essential+™, Alpha-Lactalbumin, Caseins, and Protein Sweeteners), and bespoke Custom Development Projects for exclusive protein assets. The flagship product BLG Essential+™ is a next-generation beta-lactoglobulin with self-affirmed GRAS status, while the pilot plant in Copenhagen (with 3060L capacity) supports upscaling and tech transfer services. The platform serves diverse industries including dairy proteins, biomaterials (spider silk via AMSilk partnership), agriculture (biopesticides), collagen, sweeteners, and biomining.

Product and service11 records
1BLG Essential+™
CategoryRecombinant protein ingredient
Description

High-purity, precision-fermented bovine beta-lactoglobulin with self-affirmed GRAS status and 45% more leucine than commercial whey protein isolates. Tasteless, stable across a wide pH range, heat-tolerant, free from lactose, cholesterol, hormones, and antibiotics. Used by food and beverage manufacturers in clear protein drinks, alternative dairy, bakery, and nutrition applications including healthy aging and GLP-1 nutrition.

2Alpha-Lactalbumin Precision Fermentation Program
CategoryRecombinant protein ingredient
Description

Shared-cost development program for bovine alpha-lactalbumin produced via precision fermentation using a Novonesis-sourced microbial strain. Aimed at premium infant formulas, functional foods, and clinical nutrition applications.

3Caseins Development Program
CategoryRecombinant protein ingredient
Description

Development program for precision-fermented caseins, the milk proteins that make up approximately 80% of cow's milk protein content. Rich in essential amino acids and used for texture and stability in food applications.

4Protein Sweeteners Development Program (Brazzein, Monellin)
CategoryRecombinant protein ingredient
Description

Development program for nature-identical protein sweeteners produced via precision fermentation, several thousand times sweeter than sucrose. Brazzein has obtained self-GRAS status in the US.

5Vegan Collagen Development Program
CategoryRecombinant protein ingredient
Description

Development program for animal-free collagen produced through precision fermentation, supporting collagen types I, II, III, V, and X. Targeted at beauty, wellness, and nutrition companies seeking authentic vegan collagen without animal involvement.

6Spider Silk Protein Development Program (AMSilk Partnership)
CategoryBiomaterials / recombinant protein
Description

Development program for extracellularly expressed spider silk proteins in partnership with AMSilk, achieving the world's first extracellular expression of spider silk proteins and scaling production for biomedical, cosmetics, textile, and industrial applications.

7Biomining Binding Proteins Development Program
CategoryRecombinant protein / industrial biotech
Description

Development program for metal-binding proteins and peptides produced via precision fermentation for sustainable extraction of rare earth minerals and metals from ores and e-waste with minimal environmental impact.

8Agricultural Biopesticides Development Program
CategoryRecombinant protein / agricultural biotech
Description

Development program for protein- and peptide-based biopesticides produced via precision fermentation as sustainable alternatives to chemical pesticides for crop protection. Includes collaboration with Biotalys on AGROBODY biocontrol products such as EVOCA NG.

9Custom Development Projects
CategoryBioprocess development services
Description

Individually designed projects dedicated to a single customer to optimize a proprietary recombinant protein, covering host optimization, production process design, downstream process development, and technology upscaling. Priced as a custom engagement with revenue recognized against project milestones.

10Development Programs
CategoryTechnology licensing and development services
Description

Shared-cost development programs in which several participants share development costs for selected nature-identical proteins, gaining access to continuously optimized technology and a license to use the resulting strains and processes. Includes an upfront development fee and ongoing technology optimization.

11Pilot Plant Services
CategoryBioprocess services
Description

Bioproduction upscaling services at 21st.BIO's Copenhagen pilot facility, including fermentation runs up to 1,200L, downstream processing equipment rental, tech transfer support, and CMO selection assistance. Quote-based pricing tailored to fermenter volumes, process time, material handling, DSP equipment, and special support needs; supports both proprietary customer strains and Development Program participants.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-23
Description

Belgian agricultural technology company Biotalys partnered with 21st.BIO in January 2026 to accelerate production of Biotalys' protein-based AGROBODY biocontrol solutions using 21st.BIO's precision fermentation platform. The collaboration aims to achieve commercially competitive costs for Biotalys' biofungicide EVOCA NG (targeting combined US/EU market of ~USD 1.2 billion). As part of the transition, Biotalys concluded its prior collaboration with Novonesis. EVOCA NG targeted for US registration in 2028-29 and EU in 2029-30.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-01-01
Description

21st.BIO licensed technology from Novozymes (now known as Novonesis) to develop large-scale production of proteins and peptides. The licensed strains have been optimized over 40+ years and are the foundation of 21st.BIO's precision fermentation platform. Novozymes technology underpins 21st.BIO's production strains, fermentation protocols, and industrial biomanufacturing capabilities.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

German biotech pioneer AMSilk partnered with 21st.BIO for large-scale production of spider silk-based proteins for biomedical, cosmetics, and textile industries. The collaboration achieved the world's first extracellular expression of spider silk proteins and scaled production to unprecedented levels. AMSilk's CEO stated: 'By partnering with 21st.BIO, we are succeeding where so many have struggled, delivering high performance precision fermentation at the right quality and cost parameters, and at a true industrial scale.' The partnership has been covered in Nature Biotechnology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global industrial biotechnology leader that originally developed and optimized the strain platform now licensed to 21st.BIO. As both 21st.BIO's licensor and a broader-market operator across enzymes, microbial bioproducts, and human/animal nutrition, Novonesis is the most strategically intertwined peer — overlapping directly in precision fermentation proteins while remaining far larger and more diversified.

TypeDirect peer
Description

US-based precision fermentation company producing animal-free whey protein (beta-lactoglobulin) via microbial fermentation. Direct competitor in 21st.BIO's flagship BLG segment, targeting the same food, beverage, and nutrition customers with a comparable technology approach and commercial stage.

TypeDirect peer
Description

Precision fermentation company developing animal-free egg proteins and other functional proteins via microbial fermentation. Comparable business model (B2B ingredient licensing), similar technology platform, and overlapping end-markets in food and beverage applications.

TypeDirect peer
Description

Israel-based precision fermentation company producing animal-free dairy proteins including caseins and whey. Direct competitor targeting the same dairy alternative protein opportunity as 21st.BIO's BLG, alpha-lactalbumin, and casein programs.

TypeDirect peer
Description

US-based precision fermentation company producing animal-free collagen and other proteins for beauty, nutrition, and food applications. Direct competitor in 21st.BIO's vegan collagen segment, with similar B2B ingredient licensing model and microbial fermentation technology.

TypeEmerging player
Description

Australia-based precision fermentation company developing animal-free dairy and other proteins at industrial scale. Emerging competitor in the same BLG and dairy protein segment, focused on scaling fermentation capacity similar to 21st.BIO's pilot-to-industrial roadmap.

TypeDirect peer
Description

US-based food ingredient company applying precision fermentation to develop animal-free proteins and fats for plant-based and alternative protein products. Comparable business model targeting food and beverage customers with fermentation-derived ingredients, including dairy and functional proteins.

TypeDirect peer
Description

Israel-based precision fermentation company producing animal-free milk proteins (beta-lactoglobulin, casein) for dairy alternatives. Direct competitor in the same precision-fermented dairy protein category with comparable B2B licensing strategy and target customers.

TypeBroad incumbent
Description

US-listed horizontal synthetic biology platform offering organism engineering, fermentation optimization, and biomanufacturing services across multiple end-markets. Operates at greater scale and broader scope than 21st.BIO, with overlapping capabilities in strain engineering and bioprocess development for industrial customers.

TypeBroad incumbent
Description

US-based carbon recycling company using gas fermentation (Clostridium) to produce ethanol and specialty chemicals. A more mature and broader industrial fermentation player that overlaps with 21st.BIO in industrial biomanufacturing technology and scale-up capabilities, though operating in a different feedstock/output domain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

21st.BIO

Industrial Biotechnology / Precision Fermentation Services21st.bio

21st.BIO is a Danish precision fermentation technology company that licenses 40+ year-old microbial strains from Novonesis to deliver industrial-scale bioproduction services for dairy proteins, biomaterials, agricultural biocontrols, sweeteners, and other recombinant proteins.

What 21st.BIO does

21st.BIO is a Danish precision fermentation technology and contract development company founded in 2020 and headquartered in Søborg, Denmark, with a US commercial office in Davis, California. The company operates a B2B platform that helps startups, ingredient suppliers, and large food/agriculture manufacturers bridge the 'valley of death' between lab-scale molecular innovation and industrial-scale protein production. Its stated customers include precision fermentation developers of dairy proteins, biomaterials, agricultural biocontrols, sweeteners, collagen, and biomining reagents.

The technology platform rests on three pillars: (1) microbial production strains licensed from Novozymes (now Novonesis) that have been genome-optimized over more than 40 years and are already used in food-grade products on the market today; (2) optimized fermentation processes; and (3) downstream recovery and purification (DSP) workflows built for scalability. 21st.BIO inherited the team of microbiologists and bioengineers who developed the strains at Novozymes, giving the company unusual institutional process knowledge. In May 2024 it opened a 3,060L pilot plant at its Copenhagen headquarters, designed as a 'mini factory' to de-risk customers' tech transfer to contract manufacturers. Named technical milestones include the world's first extracellular expression of spider silk proteins (with AMSilk) and customer market entry for beta-lactoglobulin in under two years from start of strain engineering.

21st.BIO earns revenue through three channels: (a) shared-cost Development Programs for nature-identical molecules such as BLG Essential+, alpha-lactalbumin, caseins, and protein sweeteners, where multiple participants pay upfront development fees and receive ongoing licensing access to continuously optimized strains and processes; (b) bespoke Custom Development Projects for proprietary customer proteins, priced per project milestones; and (c) quote-based Pilot Plant Services offering fermentation runs up to 1,200L, DSP equipment rental, and CMO tech-transfer support. The business model is explicitly backloaded to follow customers' commercial journey, aligning 21st.BIO's monetization with downstream product success. EUR 86 million in funding from Novo Holdings (December 2021) is allocated to capacity expansion and construction of the company's first manufacturing site.

21st.BIO firmographics

Firmographics
Name
21st.BIO
Legal name
21st.BIO
Website
https://21st.bio
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
21st.BIO is a Danish precision fermentation technology company that licenses 40+ year-old microbial strains from Novonesis to deliver industrial-scale bioproduction services for dairy proteins, biomaterials, agricultural biocontrols, sweeteners, and other recombinant proteins.
Ownership category
akta.pro rank

21st.BIO industry classification

Industry
Product category
Industrial Biotechnology / Precision Fermentation Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Food And Kindred Products (2000)
akta.pro industry
PRIMARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYAFAJAHAH
Fermentation-Derived Proteins (Precision Fermentation, Biomass Fermentation)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFAJAHAL
Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYHLAAAKAF
Process Development & Tech Transfer Services (upstream/downstream)

Keywords

  • Precision fermentation services
  • Industrial biotechnology
  • Microbial strain engineering
  • Recombinant protein production
  • Fermentation scale-up

Where 21st.BIO is headquartered

Location

Headquarters

HQ city
Søborg
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

21st.BIO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Development Programs (Nature-Identical Molecules): 21st.BIO selects a few natural proteins (e.g., beta-lactoglobulin, caseins) to be offered through development programs. Several companies share development costs, gaining access to continuously optimized technology and a license to use the strains and processes. This shared-cost model significantly de-risks investment into precision fermentation production. Participants pay an upfront development fee and receive ongoing access to technology optimization.
  2. Custom/Bespoke Development Projects: Individually designed projects to optimize a customer's proprietary recombinant protein. Dedicated project to a single customer encompassing activities including strain optimization, production process design, DSP development, and technology upscaling. Priced as a custom engagement; revenue recognized upon project milestones.
  3. Pilot Plant Services: 21st.BIO offers bioproduction upscaling services at its Copenhagen pilot facility, including fermentation runs up to 1,200L and DSP equipment rental. Services are available to customers with their own proprietary strains as well as existing customers in development programs. Pricing is quote-based, tailored to fermenter volumes, process time, material handling, DSP equipment, and special support needs.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

21st.BIO product offering

Product offering

Core offering

21st.BIO provides industrial-scale precision fermentation technology and services for protein and peptide production, combining 40+ year-old microbial production strains licensed from Novozymes/Novonesis with optimized fermentation processes and downstream recovery/purification workflows. Customers engage through shared-cost Development Programs for nature-identical molecules (BLG, alpha-lactalbumin, caseins, sweeteners, collagen, biomaterials, biomining proteins) or through bespoke Custom Development Projects for proprietary proteins, supported by a 3,060L Copenhagen pilot plant for upscaling and tech transfer to contract manufacturers.

Product overview

21st.BIO operates a precision fermentation technology platform that provides end-to-end solutions for industrial-scale protein and peptide production. The platform consists of proprietary production strains licensed from Novonesis (with 40+ years of optimization), optimized fermentation processes, and downstream processing (DSP) workflows. The company offers two engagement models: shared-cost Development Programs for nature-identical molecules (including BLG Essential+™, Alpha-Lactalbumin, Caseins, and Protein Sweeteners), and bespoke Custom Development Projects for exclusive protein assets. The flagship product BLG Essential+™ is a next-generation beta-lactoglobulin with self-affirmed GRAS status, while the pilot plant in Copenhagen (with 3060L capacity) supports upscaling and tech transfer services. The platform serves diverse industries including dairy proteins, biomaterials (spider silk via AMSilk partnership), agriculture (biopesticides), collagen, sweeteners, and biomining.

Differentiator

Problem solved

Functional benefit

Brands

  • BLG Essential+™: A high-leucine, animal-free beta-lactoglobulin produced through precision fermentation, designed for food applications including healthy aging and GLP-1 nutrition.

Products and services

  • BLG Essential+™ High-purity, precision-fermented bovine beta-lactoglobulin with self-affirmed GRAS status and 45% more leucine than commercial whey protein isolates. Tasteless, stable across a wide pH range, heat-tolerant, free from lactose, cholesterol, hormones, and antibiotics. Used by food and beverage manufacturers in clear protein drinks, alternative dairy, bakery, and nutrition applications including healthy aging and GLP-1 nutrition.
  • Alpha-Lactalbumin Precision Fermentation Program Shared-cost development program for bovine alpha-lactalbumin produced via precision fermentation using a Novonesis-sourced microbial strain. Aimed at premium infant formulas, functional foods, and clinical nutrition applications.
  • Caseins Development Program Development program for precision-fermented caseins, the milk proteins that make up approximately 80% of cow's milk protein content. Rich in essential amino acids and used for texture and stability in food applications.
  • Protein Sweeteners Development Program (Brazzein, Monellin) Development program for nature-identical protein sweeteners produced via precision fermentation, several thousand times sweeter than sucrose. Brazzein has obtained self-GRAS status in the US.
  • Vegan Collagen Development Program Development program for animal-free collagen produced through precision fermentation, supporting collagen types I, II, III, V, and X. Targeted at beauty, wellness, and nutrition companies seeking authentic vegan collagen without animal involvement.
  • Spider Silk Protein Development Program (AMSilk Partnership) Development program for extracellularly expressed spider silk proteins in partnership with AMSilk, achieving the world's first extracellular expression of spider silk proteins and scaling production for biomedical, cosmetics, textile, and industrial applications.
  • Biomining Binding Proteins Development Program Development program for metal-binding proteins and peptides produced via precision fermentation for sustainable extraction of rare earth minerals and metals from ores and e-waste with minimal environmental impact.
  • Agricultural Biopesticides Development Program Development program for protein- and peptide-based biopesticides produced via precision fermentation as sustainable alternatives to chemical pesticides for crop protection. Includes collaboration with Biotalys on AGROBODY biocontrol products such as EVOCA NG.
  • Custom Development Projects Individually designed projects dedicated to a single customer to optimize a proprietary recombinant protein, covering host optimization, production process design, downstream process development, and technology upscaling. Priced as a custom engagement with revenue recognized against project milestones.
  • Development Programs Shared-cost development programs in which several participants share development costs for selected nature-identical proteins, gaining access to continuously optimized technology and a license to use the resulting strains and processes. Includes an upfront development fee and ongoing technology optimization.
  • Pilot Plant Services Bioproduction upscaling services at 21st.BIO's Copenhagen pilot facility, including fermentation runs up to 1,200L, downstream processing equipment rental, tech transfer support, and CMO selection assistance. Quote-based pricing tailored to fermenter volumes, process time, material handling, DSP equipment, and special support needs; supports both proprietary customer strains and Development Program participants.

Quantifiable outcome

  • Market entry achieved in under two years from start of strain engineering for beta-lactoglobulin customers
  • +5 more outcomes

Companies that use 21st.BIO

Customer profile

Named customers2 records

Segments6 records

Ideal customer profiles4 records

21st.BIO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

21st.BIO partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • BiotalysflagshipStrategic or Co-development Partner · 23 January 2026Belgian agricultural technology company Biotalys partnered with 21st.BIO in January 2026 to accelerate production of Biotalys' protein-based AGROBODY biocontrol solutions using 21st.BIO's precision fermentation platform. The collaboration aims to achieve commercially competitive costs for Biotalys' biofungicide EVOCA NG (targeting combined US/EU market of ~USD 1.2 billion). As part of the transition, Biotalys concluded its prior collaboration with Novonesis. EVOCA NG targeted for US registration in 2028-29 and EU in 2029-30.
  • Novozymes (now Novonesis)coreTechnology or Integration · 1 January 202021st.BIO licensed technology from Novozymes (now known as Novonesis) to develop large-scale production of proteins and peptides. The licensed strains have been optimized over 40+ years and are the foundation of 21st.BIO's precision fermentation platform. Novozymes technology underpins 21st.BIO's production strains, fermentation protocols, and industrial biomanufacturing capabilities.
  • AMSilkflagshipStrategic or Co-development PartnerGerman biotech pioneer AMSilk partnered with 21st.BIO for large-scale production of spider silk-based proteins for biomedical, cosmetics, and textile industries. The collaboration achieved the world's first extracellular expression of spider silk proteins and scaled production to unprecedented levels. AMSilk's CEO stated: 'By partnering with 21st.BIO, we are succeeding where so many have struggled, delivering high performance precision fermentation at the right quality and cost parameters, and at a true industrial scale.' The partnership has been covered in Nature Biotechnology.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

21st.BIO competitors and assessment

Company assessment

Broad incumbents

  • Novonesis (formerly Novozymes): Global industrial biotechnology leader that originally developed and optimized the strain platform now licensed to 21st.BIO. As both 21st.BIO's licensor and a broader-market operator across enzymes, microbial bioproducts, and human/animal nutrition, Novonesis is the most strategically intertwined peer — overlapping directly in precision fermentation proteins while remaining far larger and more diversified.
  • Ginkgo Bioworks: US-listed horizontal synthetic biology platform offering organism engineering, fermentation optimization, and biomanufacturing services across multiple end-markets. Operates at greater scale and broader scope than 21st.BIO, with overlapping capabilities in strain engineering and bioprocess development for industrial customers.
  • LanzaTech: US-based carbon recycling company using gas fermentation (Clostridium) to produce ethanol and specialty chemicals. A more mature and broader industrial fermentation player that overlaps with 21st.BIO in industrial biomanufacturing technology and scale-up capabilities, though operating in a different feedstock/output domain.

Direct peers

  • Perfect Day: US-based precision fermentation company producing animal-free whey protein (beta-lactoglobulin) via microbial fermentation. Direct competitor in 21st.BIO's flagship BLG segment, targeting the same food, beverage, and nutrition customers with a comparable technology approach and commercial stage.
  • The EVERY Company (formerly Clara Foods): Precision fermentation company developing animal-free egg proteins and other functional proteins via microbial fermentation. Comparable business model (B2B ingredient licensing), similar technology platform, and overlapping end-markets in food and beverage applications.
  • Imagindairy: Israel-based precision fermentation company producing animal-free dairy proteins including caseins and whey. Direct competitor targeting the same dairy alternative protein opportunity as 21st.BIO's BLG, alpha-lactalbumin, and casein programs.
  • Geltor: US-based precision fermentation company producing animal-free collagen and other proteins for beauty, nutrition, and food applications. Direct competitor in 21st.BIO's vegan collagen segment, with similar B2B ingredient licensing model and microbial fermentation technology.
  • Motif FoodWorks: US-based food ingredient company applying precision fermentation to develop animal-free proteins and fats for plant-based and alternative protein products. Comparable business model targeting food and beverage customers with fermentation-derived ingredients, including dairy and functional proteins.
  • Remilk (Better Milk): Israel-based precision fermentation company producing animal-free milk proteins (beta-lactoglobulin, casein) for dairy alternatives. Direct competitor in the same precision-fermented dairy protein category with comparable B2B licensing strategy and target customers.

Emerging players

  • Cauldron: Australia-based precision fermentation company developing animal-free dairy and other proteins at industrial scale. Emerging competitor in the same BLG and dairy protein segment, focused on scaling fermentation capacity similar to 21st.BIO's pilot-to-industrial roadmap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

21st.BIO social profiles

Digital presence

21st.BIO compliance and trust

Trust signal

Compliance2 records

21st.BIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

21st.BIO leadership team

Management profile

Number of profiles

Profiles1 record

21st.BIO funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

21st.BIO M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 21st.BIO

What does 21st.BIO do?

21st.BIO provides industrial-scale precision fermentation technology and services for protein and peptide production, combining 40+ year-old microbial production strains licensed from Novozymes/Novonesis with optimized fermentation processes and downstream recovery/purification workflows. Customers engage through shared-cost Development Programs for nature-identical molecules (BLG, alpha-lactalbumin, caseins, sweeteners, collagen, biomaterials, biomining proteins) or through bespoke Custom Development Projects for proprietary proteins, supported by a 3,060L Copenhagen pilot plant for upscaling and tech transfer to contract manufacturers.

Is 21st.BIO a public or private company?

21st.BIO is a private company. It is classified as venture growth investor backed and is currently operating.

When was 21st.BIO founded?

21st.BIO was founded in 2020. It employs 51 to 100 people.

Where is 21st.BIO based?

21st.BIO is headquartered in Søborg, Denmark, in the Europe region.

How does 21st.BIO make money?

Three revenue lines are on record. Development Programs (Nature-Identical Molecules) is the primary driver. The others are custom/Bespoke Development Projects and pilot Plant Services.

Who are 21st.BIO's main competitors?

Broad incumbents on record are Novonesis (formerly Novozymes), Ginkgo Bioworks and LanzaTech. Direct peers are Perfect Day, The EVERY Company (formerly Clara Foods), Imagindairy, Geltor, Motif FoodWorks and Remilk (Better Milk). Cauldron is listed as an emerging player.

Does 21st.BIO have an API?

No public API is recorded for 21st.BIO.

What industry is 21st.BIO in?

21st.BIO's product category is Industrial Biotechnology / Precision Fermentation Services. Its primary akta.pro industry code is HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling), with a secondary code of AFAJAHAH, Fermentation-Derived Proteins (Precision Fermentation, Biomass Fermentation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
vegconomist21st.BIO Files EU Novel Food Application for Animal-Free BLG and Calls for a Fast-Track Approval Route21st.BIO filed an EU novel food application for BLG Essential+, a beta-lactoglobulin production technology, and requested a fast-track approval route. The company argues that well-characterized, nature-identical proteins should face lower regulatory requirements. It targets high-protein nutrition for older adults and weight-loss users.Third News21st.BIO Pushes for Acceptance of BLG Essential+ in Europe to Enhance Protein Production21st.BIO submitted an EU Novel Food application for BLG Essential+, a precision-fermented beta-lactoglobulin protein. The product aims to address European whey protein supply constraints and urges regulators for a science-based approval route. The company cites potential benefits for vulnerable groups and future markets.Aktien21st.BIO files EU Novel Food application for BLG Essential+ and calls for a European home market for industrially proven precision fermentation technology for production of food21st.BIO filed an EU Novel Food application for BLG Essential+, its precision-fermented bovine beta-lactoglobulin, following US regulatory approval in October 2025. The company calls for a predictable EU approval process and a European home market to commercialize the technology. The filing aims to address supply constraints in the European whey protein market.PR Newswire21st.BIO files EU Novel Food application for BLG Essential+™ and calls for a European home market for industrially proven precision fermentation technology for production of food21st.BIO filed an EU Novel Food application for BLG Essential+, its precision-fermented bovine beta-lactoglobulin, following US regulatory approval in October 2025. The company calls for a fast-track pathway for well-characterized, nature-identical food proteins to strengthen European protein supply and attract investment.news.cision.com21st.BIO files EU Novel Food application for BLG Essential+™ and calls for a European home market for industrially proven precision fermentation technology for production of food21st.BIO filed an EU Novel Food application for BLG Essential+, its precision-fermented bovine beta-lactoglobulin, following US approval in October 2025. The company calls for a fast-track EU approval pathway for well-characterized, nature-identical food proteins. It cites a 2025 study showing the strain is mycotoxin-free and lacks penicillin G gene clusters.AgFunderNews🎥 Future Food-Tech: Big ideas, hard truths, and the path to scaleAt the Future Food-Tech event in San Francisco, industry stakeholders discussed challenges and advances in biomanufacturing, fermentation technology, and AI-driven food product development across multiple company interviews. Companies including Checkerspot, 21st.Bio, Fermelanta, Michroma, Laurus Bio, Kawa Project, Bettani Farms, Totality Biosciences, and Dogodan shared insights on scaling production from lab to commercial scale, with projections that precision-fermented proteins could reach below $10 per kilogram within years. The Institute of Food Technologists also unveiled its AI-powered CoDeveloper platform designed to accelerate food product development using 85 years of proprietary scientific knowledge.GreenhousemagBiotalys and 21st.BIO partner on biocontrol productionBiotalys, a Belgian agricultural technology company, has partnered with Danish precision fermentation firm 21st.BIO to scale production of its protein-based biocontrol solutions, leveraging 21st.BIO's fermentation platform. The collaboration aims to reduce costs and support the commercialization of Biotalys’ EVOCA NG biocontrol product, with regulatory approval planned for 2028-29 in the U.S.ProducegrowerBiotalys and 21st.BIO partner on biocontrol productionBelgium-based agricultural technology company Biotalys and Danish precision fermentation company 21st.BIO have entered into a strategic partnership to accelerate production of Biotalys' protein-based biocontrol solutions at commercially competitive costs. The collaboration leverages 21st.BIO's fermentation platform, licensed in part from Novonesis, to support large-scale manufacturing of Biotalys' AGROBODY products, including the upcoming biofungicide EVOCA NG. Biotalys' first-generation product EVOCA received U.S. EPA approval in December 2025, with EVOCA NG targeted for commercial launch in 2028-29 in the U.S. and 2029-30 in the E.U.Growing ProduceProgress on Protein-Based Biocontrol Option for Produce GrowersBiotalys and 21st.BIO, a Danish precision fermentation technology company, partnered to accelerate the production of Biotalys' protein-based biocontrol solutions. The collaboration will utilize 21st.BIO's proprietary fermentation platform to support large-scale manufacturing at competitive costs.